• STAT+: PTC's Duchenne muscular dystrophy drug achieves study goal, potentially confirming European approval

    12 days ago - By STAT

    PTC Therapeutics said Tuesday that its treatment for Duchenne muscular dystrophy slowed the loss of muscle function in patients in a randomized clinical trial designed to keep the drug on the market in Europe.
    But a separate analysis of the same study data that might allow PTC to seek approval in the U.S. failed to reach statistical significance. Continue to STAT+ to read the full story...
    Read more ...